|
Acambis – Raising awareness of
Acambis’ universal flu vaccine, ACAM-FLU-A
Acambis is a UK-listed biotech company targeting infectious diseases with novel vaccines. Its ACAM-FLU-A product is a universal vaccine that targets A strains of the influenza virus, including pandemic strains. By targeting a conserved protein, the vaccine could overcome the current need to adapt influenza vaccines every year to correspond to circulating strains. Acambis announced positive results for both a Phase I trial and a preclinical trial that tested the ability of the vaccine to tackle H5N1 influenza in January 2008.
Our task:
- Raise awareness of ACAM-FLU-A following announcement preclinical and Phase I
clinical data to target the following groups:
- Potential partners - by securing coverage in USA and European trade
publications
- Retail shareholders - by securing coverage in UK national media
- Arrange media briefings for Ian Garland, CEO of Acambis at investor conference
Our methods:
- Following a
briefing call with client, College Hill drafted press release, detailed Q&A for
media use, and a draft project strategy document including a schedule of actions
- Obtained list of media attending
JP Morgan conference and contacted them to secure meetings for Ian Garland
- Identified and approached independent key
opinion leaders who would be happy to comment on universal flu vaccine
development
- Distributed press release to trade and UK
national healthcare media contacts
- Proactively followed up with
key target press to secure interviews with spokespeople
- Identified opportunities for future trade
and national media coverage for Acambis and pitched ideas to company
Our results:
- The story was covered in The
Times, Daily Telegraph, Daily Mail, Daily Star, Daily Express, BBC News online
and New Scientist
- Trade press coverage included BioCentury,
BioWorld International, Pharma Times, Scrip, Fierce Biotech and Nature
- Syndicated stories were published on
websites around the world
- A second interview was secured with the
Daily Mail on Acambis' C. difficile vaccine, which resulted in front page
coverage and follow-on pieces in a wide range of publications including Daily
Telegraph, Daily Express, The Sun, Daily Mirror, BBC News online and Channel 4
online
- Article opportunities were identified in
Drug and Market Development and EBR
Client Endorsement
Lyndsay Wright, VP, Communications and IR at
Acambis said: "I just wanted to say what a great job you and the team have
done with this one - the coverage is phenomenal."
March 2008
To discuss our capability in this area please contact:
Lorna Cuddon, Account Director
+44 (0)207 457 2020
lorna.cuddon@collegehill.com |
Quick links
